The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia RheumaticaSarah Mackie, Frank Buttgereit, Chetan Mukhtyar et al.|The Journal of Rheumatology|2017Cited by 46
A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest GroupRachel Black, Catherine Hill, Joanna Robson et al.|The Journal of Rheumatology|2017Cited by 22
Changes in serum levels of type I and III procollagen extension peptides during infusion of human parathyroid hormone fragment (1–34)Lee S. Simon, Stephen M. Krane, David M. Slovik et al.|Journal of Bone and Mineral Research|1988Cited by 21
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Catherine Hill, Jonathan TL. Cheah et al.|Seminars in Arthritis and Rheumatism|2021Cited by 12
Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working GroupJonathan T. L. Cheah, Catherine Hill, Rachel Black et al.|The Journal of Rheumatology|2019Cited by 10